The histone methyltransferase EZH2, an oncogene common to benign and malignant parathyroid tumors

Endocrine-Related Cancer

Volumn 21, Issue 2, 2014, Pages 231-239

  Svedlund, Jessica ^a   Barazeghi, Elham ^a   Stålberg, Peter ^a   Hellman, Per ^a   Åkerström, Göran ^a   Björklund, Peyman ^a   Westin, Gunnar ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Axin2; EZH2; Gene amplification; Hyperparathyroidism; PRC2; catenin

Indexed keywords

AXIN; AXIN2 PROTEIN; BETA CATENIN; HISTONE METHYLTRANSFERASE; THYMIDINE; TRANSCRIPTION FACTOR EZH2; TRITIUM; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DNA SYNTHESIS; GENE AMPLIFICATION; HUMAN; HUMAN CELL; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID CELL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN STABILITY; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AXIN2; EZH2; GENE AMPLIFICATION; HYPERPARATHYROIDISM; PRC2; Β-CATENIN;

ADENOMA; CARCINOMA; HUMANS; HYPERPARATHYROIDISM, SECONDARY; ONCOGENES; PARATHYROID GLANDS; PARATHYROID NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2; RNA, MESSENGER; WNT SIGNALING PATHWAY;

EID: 84899885934     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0497     Document Type: Article

References (36)

1. Akerstrom G & Hellman P 2004 Primary hyperparathyroidism. Current Opinion in Oncology 16 1-7.
2. Björklund P & Akerstrom G 2009 Molecular genetics of parathyroid disease. World Journal of Surgery 33 2224-2233. (doi:10.1007/s00268-009-0022-6)
3. Björklund P, Akerström G & Westin G 2007a Activated b-catenin in the novel human parathyroid tumor cell line sHPT-1. Biochemical and Biophysical Research Communications 352 532-536. (doi:10.1016/j.bbrc.2006.11. 056)
4. Björklund P, Akerström G & Westin G 2007b Accumulation of non-phosphorylated b-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors. Journal of Clinical Endocrinology and Metabolism 92 338-344. (doi:10.1210/jc.2006-1197)
5. Björklund P, Akerström G & Westin G 2007c An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT/b-catenin signaling. PLoS Medicine 4 e328. (doi:10.1371/journal. pmed.0040328)
6. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E & Helin K 2003 EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO Journal 22 5323-5335. (doi:10.1093/emboj/cdg542)
7. Chang CJ & Hung MC 2012 The role of EZH2 in tumor progression. British Journal of Cancer 106 243-247. (doi:10.1038/bjc.2011.551)
8. Chase A & Cross NC 2011 Aberrations of EZH2 in cancer. Clinical Cancer Research 17 2613-2618. (doi:10.1158/1078-0432.CCR-10-2156)
9. Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH et al. 2011 EZH2-mediated concordant repression of Wnt antagonists promotes b-catenin-dependent hepatocarcinogenesis. Cancer Research 71 4028-4039. (doi:10.1158/0008-5472.CAN-10-3342)
10. Clevers H & Nusse R 2012 Wnt/b-catenin signaling and disease. Cell 149 1192-1205. (doi:10.1016/j.cell.2012.05.012)
11. Costa-Guda J & Arnold A 2013 Genetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumors. Molecular and Cellular Endocrinology [in press]. (doi:10.1016/j.mce.2013.09.005)
12. Cromer MK, Starker LF, Choi M, Udelsman R, Nelson-Williams C, Lifton RP & Carling T 2012 Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. Journal of Clinical Endocrinology and Metabolism 97 E1774-E1781. (doi:10.1210/jc.2012-1743)
13. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J et al. 2009 Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114 2733-2743. (doi:10.1182/blood-2009-03-213496)
14. Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Fälth M, Sültmann H, Holzer A, Hoppe-Seyler K & Hoppe-Seyler F 2011 EZH2 depletion blocks the proliferation of colon cancer cells. PLoS ONE 6 e21651. (doi:10.1371/journal.pone.0021651)
15. Gao SB, Feng ZJ, Xu B, Wu Y, Yin P, Yang Y, Hua X & Jin GH 2009 Suppression of lung adenocarcinoma through menin and polycomb gene-mediated repression of growth factor pleiotrophin. Oncogene 28 4095-4104. (doi:10.1038/onc.2009.273)
16. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S & De Marxo AM 2011 Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2 669-683.
17. Lemos MC & Thakker RV 2008 Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Human Mutation 29 22-32. (doi:10.1002/humu.20605)
18. Li X, Gonzalez ME, Toy K, Filzen T, Merajver SD & Kleer CG 2009 Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. American Journal of Pathology 175 1246-1254. (doi:10.2353/ajpath.2009.090042)
19. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG & Hung MC 2000 b-Catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. PNAS 97 4262-4266. (doi:10.1073/pnas.060025397)
20. Margueron R & Reinberg D 2011 The polycomb complex PRC2 and its mark in life. Nature 469 343-349. (doi:10.1038/nature09784)
21. Marx SJ 2000 Hyperparathyroid and hypoparathyroid disorders. New England Journal of Medicine 343 1863-1875. (doi:10.1056/NEJM200012213432508)
22. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, Marquez VE & Jones PA 2009 DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Molecular Cancer Therapeutics 8 1579-1588. (doi:10.1158/1535-7163. MCT-09-0013)
23. Newey PJ, Nesbit MA, Rimmer AJ, Attar M, Head RT, Christie PT, Gorvin CM, Stechman M, Gregory L, Mihai R et al. 2012 Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism 97 E1995-E2005. (doi:10.1210/jc.2012-2303)
24. van Noort M, Meeldijk J, van der Zee R, Destree O & Clevers H 2002 Wnt signaling controls the phosphorylation status of b-catenin. Journal of Biological Chemistry 277 17901-17905. (doi:10.1074/jbc.M111635200)
25. O'Meara MM & Simon JA 2012 Inner workings and regulatory inputs that control polycomb repressive complex 2. Chromosoma 121 221-234. (doi:10.1007/s00412-012-0361-1)
26. Saramaki OR, Tammela TL, Martikainen PM, Vessella RL & Visakorpi T 2006 The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes, Chromosomes & Cancer 45 639-645. (doi:10.1002/gcc.20327)
27. Sharretts JM & Simonds WF 2010 Clinical and molecular genetics of parathyroid neoplasms. Best Practice & Research. Clinical Endocrinology & Metabolism 24 491-502. (doi:10.1016/j.beem.2010.01.003)
28. Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, Sun L, Zhang Y, Chen Y, Li R et al. 2007 Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Molecular and Cellular Biology 27 5105-5119. (doi:10.1128/MCB.00162-07)
29. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R & Ben-Ze'ev A 1999 The cyclin D1 gene is a target of the b-catenin/LEF-1 pathway. PNAS 96 5522-5527. (doi:10.1073/pnas.96.10.5522)
30. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM & Copeland RA 2010 Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. PNAS 107 20980-20985. (doi:10.1073/pnas.1012525107)
31. Svedlund J, Aurén M, Sundström M, Dralle H, Akerström G, Björklund P & Westin G 2010 Aberrant WNT/b-catenin signaling in parathyroid carcinoma. Molecular Cancer 9 294. (doi:10.1186/1476-4598-9-294)
32. Svedlund J, Koskinen Edblom S, Marquez VE, Akerström G, Björklund P & Westin G 2012 Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine modification. Journal of Clinical Endocrinology and Metabolism 97 E1307-E1315. (doi:10.1210/jc.2011-3136)
33. Westin G, Björklund P & Akerstrom G 2009 Molecular genetics of parathyroid disease. World Journal of Surgery 33 2224-2233. (doi:10.1007/s00268- 009-0022-6)
34. Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx SJ & Simonds WF 2005 Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 24 1272-1276. (doi:10.1038/sj.onc.1208274)
35. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T et al. 2012 EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science 338 1465-1469. (doi:10.1126/science. 1227604)
36. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M et al. 2011 Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117 2451-2459. (doi:10.1182/blood-2010- 11-321208)